Figure 1.

Cumulative incidence of invasive fungal infections (IFI) of patients receiving haploidentical stem cell transplantation (Haplo‐SCT) with post‐transplant cyclophosphamide (PT‐Cy): (A) day‐100 cumulative incidence of possible‐proven‐probable IFI of patients receiving caspofungin as primary antifungal prophylaxis; (B) day‐100 cumulative incidence of proven‐probable IFI of patients receiving caspofungin as primary antifungal prophylaxis; and (C) comparison of day‐100 cumulative incidence of proven‐probable IFI between patients receiving caspofungin or itraconazole as primary antifungal prophylaxis